Transgenic animal models for thrombocytopenia
AssigneeAmgen Inc.
InventorsMurray O. Robinson, Pamela Hunt, Robert A. Bosselman
Life of this patent
Estimating the term…
Abstract
Transgenic mice and methods of preparing such mice are disclosed. The mice exhibit decreased platelet counts and/or megakaryocyte leukemia.
Claims5
A vector comprising a nucleic acid molecule encoding the SV40 early region tsA58 mutant operably linked to a rat PF4 promoter.
A mouse expressing a transgene stably incorporated into its DNA, wherein the transgene comprises the DNA encoding the SV40 early region tsA58 mutant operably linked to a rat PF4 promoter, and expression of the transgene causes thrombocytopenia or megakaryocyte leukemia.
A method of preparing a mouse with thrombocytopenia, comprising:
- a) introducing into a fertilized mouse embryo a DNA molecule encoding the SV40 early region tsA58 mutant operably linked to a rat PF4 promoter;
- b) implanting said embryo into a surrogate mother to produce offspring;
- and
- c) screening said offspring for decreased platelet counts.
A method of preparing a mouse with megakaryocyte leukemia, comprising:
- a) introducing into a fertilized mouse embryo a DNA molecule encoding the SV40 early region tsA58 mutant operably linked to a rat PF4 promoter;
- b) implanting said embryo into a surrogate mother to produce offspring;
- and
- c) screening said offspring for megakaryocyte leukemia.
Dependencies are inferred from the claim text.